A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly) [PDF]
Veronika Ballová+14 more
openalex +1 more source
Treatment‐related infertility is of great concern to younger long‐term survivors of acute leukaemia (AL). The literature on fertility outcomes in adult long‐term AL survivors is limited, mainly focused on stem cell transplantation or childhood leukaemia, with little information on the use of assisted reproduction technology.
Nanna N. Nielsen+10 more
wiley +1 more source
Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD-1 blockade. [PDF]
Kuczmarski TM, Lynch RC.
europepmc +1 more source
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley +1 more source
Clinical features and outcomes of newly diagnosed classical Hodgkin lymphoma patients in Saudi Arabia: a multicenter cohort study. [PDF]
Alalawi M+22 more
europepmc +1 more source
The German multinational GPOH-HD 95 trial: Treatment results and analysis of failures in pediatric Hodgkins disease using combination chemotherapy with and without radiation [PDF]
U RUHL+4 more
openalex +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen+3 more
wiley +1 more source
ΔSUVmax adds prognostic value to early response assessment during the first-line treatment of classical hodgkin lymphoma: a retrospective cohort study. [PDF]
Pinczés LI+7 more
europepmc +1 more source